STAT+: Pharmalittle: Amgen ends two lupus programs; Illumina sequencers have security vulnerability
Hello and happy Friday, with STAT reporter Andrew Joseph here steering the ship in place of Ed for the day. We’re treating ourselves to a cappuccino at the moment, which will perhaps inspire some of you to get yourself your own Friday reward. Or maybe the promise of a weekend is all that you need to get you through today. In the meantime, a few headlines for you. …
In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow, as far as patient advocacy groups were concerned, but that glow is fading, STAT writes. On one hand, a new survey found, 60% of patient groups believed brand-name drugmakers maintained an “excellent” or “good” corporate reputation in 2022, which was up ever-so-slightly from 59% the year before. But just 32% of these groups reported that the 42 brand-name companies examined did an “excellent” or “good” job of improving access to medicines last year. By comparison, 52% thought the companies did a “fair” to “poor” job of providing access.
Continue to STAT+ to read the full story…
